Ensuring that all frontline clinicians are equipped, confident, and engaged in executing skilled communication, which is at the core of palliative care, will make a significant difference for how value-based care unfolds, how payment reform happens, and how the lived experience plays out for patients and families to be a better one, said Rebecca Kirch, JD, executive vice president, Health Care, Quality and Value, National Patient Advocate Foundation.
Ensuring that all frontline clinicians are equipped, confident, and engaged in executing skilled communication, which is at the core of palliative care, will make a significant difference for how value-based care unfolds, how payment reform happens, and how the lived experience plays out for patients and families to be a better one, said Rebecca Kirch, JD, executive vice president, Health Care, Quality and Value, National Patient Advocate Foundation.
Transcript
What obstacles continue to prove an issue within oncology? What further research is warranted to address these issues?
There are some interesting challenges in the form of language barriers and old habits that die hard. On the panel this morning, we talked about the importance of integrating palliative care, and the first question was, well who provides that? Depending on when you were trained in your practice, you might have learned palliative care as something different from what it is today and what the evidence shows. So today, what Palliative care is, is an essential aspect of good quality cancer care from diagnosis onward to optimize quality-of-life.
Whose job is it? It's everybody's job. Every clinical encounter needs to include some aspects of helping with care coordination, identifying what's bothering the patient and caregiver most, because they're an essential unit of care. The opportunity we have to use the skilled communication that is sort of at the core palliative care principle for all frontline clinicians to be equipped and confident and engaged in doing, I think will make a significant difference for how value-based care unfolds, how payment reform happens, how the lived experience plays out for patients and families to be a better one, irrespective of the prognosis of the trajectory.
If we emphasize the importance of those skills, and the opportunities to address financial impairments and functional impairments through navigation to these services that people need that focus on what they say matters to them, then we're delivering truly person-centered care and the promise of what that can be. If we keep emphasizing disease-directed treatment without thinking about quality-of-life, and the person beyond the disease, we're going to fall short of all of those goals that we all hold dear.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More